Despite inconsistent results in clinical trials for idiopathic pulmonary fibrosis, CTGF remains a central player in fibrosis and could still serve as a potential therapeutic target for orbital fibrosis in GO patients. Here, CCN2 is linked to pulmonary fibrosis.